Read by QxMD icon Read


Zhongzhi Jia, Guomin Jiang, Feng Tian, Chunfu Zhu, Xihu Qin
BACKGROUND/AIM: Over the past two decades, several advances have been made in the management of patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT). Yttrium-90 ( 90 Y) radioembolization has recently been made a treatment option for patients with HCC and PVTT. However, there is still a need to systematicly evaluate the outcomes of 90 Y radioembolization for HCC and PVTT. We aimed to assess the safety and effectiveness of 90 Y radioembolization for HCC and PVTT...
September 2016: Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association
Suresh Subramanian, Usha Pandey, Pradip Chaudhari, Monica Tyagi, Sanjay Gupta, Geetanjali Singh, Ashutosh Dash, Grace Samuel, Meera Venkatesh
BACKGROUND & OBJECTIVES: Yttrium-90 ( 90 Y)-based radioembolization has been employed to treat hepatocellular carcinoma (HCC) as commercial radioactive glass and polymeric resin microspheres. However, in India and other Asian countries, these preparations must be imported and are expensive, validating the need for development of indigenous alternatives. This work was aimed to develop an economically and logistically favourable indigenous alternative to imported radioembolizing agents for HCC therapy...
May 2016: Indian Journal of Medical Research
Suresh de Silva, Simon Mackie, Peter Aslan, David Cade, Warick Delprado
BACKGROUND: Intra-arterial brachytherapy with yttrium-90 ((90)Y) resin microspheres (radioembolization) is a procedure to selectively deliver high-dose radiation to tumors. The purpose of this research was to compare the radioembolic effect of (90)Y-radioembolization versus the embolic effect of bland microspheres in the porcine kidney model. METHODS: In each of six pigs, ~25-33 % of the kidney volume was embolized with (90)Y resin microspheres and an equivalent number of bland microspheres in the contralateral kidney...
October 14, 2016: Cardiovascular and Interventional Radiology
Stephan Walrand, Michel Hesse, François Jamar
After a brief history of the major evolutions of PET since its introduction in 1972, this paper reviews the recent improvements and novel trends in PET with a special focus on time of flight that is currently the major research topic. Novel emerging acquisition modalities, such as dual tracer acquisition, inline hadron therapy dose imaging and yttrium-90 imaging are reviewed.
October 12, 2016: British Journal of Radiology
Clara Ferreira, Daniel Johnson, Karl Rasmussen, Clinton Leinweber, Salahuddin Ahmad, Jae Won Jung
PURPOSE: To develop a novel conformal superficial brachytherapy (CSBT) device as a treatment option for the patient-specific radiation therapy of conditions including superficial lesions, postsurgical positive margins, Dupuytren's contractures, keloid scars, and complex anatomic sites (eyelids, nose, ears, etc.). METHODS AND MATERIALS: A preliminary CSBT device prototype was designed, built, and tested using readily available radioactive seeds. Iodine-125 ((125)I) seeds were independently guided to the treatment surface to conform to the target...
October 3, 2016: Brachytherapy
Michel Rayar, Giovanni Battista Levi Sandri, Pauline Houssel-Debry, Christophe Camus, Laurent Sulpice, Karim Boudjema
Treatment of intrahepatic cholangiocarcinoma remains a major challenge. For an unresectable lesion without extrahepatic spread, liver transplantation could be a potential solution but it is still associated with poor oncologic results owing to the absence of effective neoadjuvant treatment. We report the case of a young man with locally advanced intrahepatic cholangiocarcinoma presenting with multiple intrahepatic metastases and vascular structure involvement. The lesion was significantly downstaged by a multimodal therapy including intra-arterial Yttrium-90 radioembolization, systemic chemotherapy and external radiotherapy, allowing liver transplantation...
September 2016: Journal of Gastrointestinal and Liver Diseases: JGLD
Lisa M Rowley, Kevin M Bradley, Philip Boardman, Aida Hallam, Daniel R McGowan
: Imaging on a gamma camera with Yttrium-90 ((90)Y) following selective internal radiotherapy (SIRT) may allow for verification of treatment delivery but suffers relatively poor spatial resolution and imprecise dosimetry calculation. (90)Y Positron Emission Tomography (PET) / Computed Tomography (CT) imaging is possible on 3D, time-of-flight machines however images are usually poor due to low count statistics and noise. A new PET reconstruction software using a Bayesian penalized likelihood (BPL) reconstruction algorithm (termed Q...
September 29, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Marcus Caine, Michael S McCafferty, Scott McGhee, Pedro Garcia, Wayne M Mullett, Xunli Zhang, Martyn Hill, Matthew R Dreher, Andrew L Lewis
PURPOSE: To investigate material density, flow, and viscosity effects on microsphere distribution within an in vitro model designed to simulate hepatic arteries. MATERIALS AND METHODS: A vascular flow model was used to compare distribution of glass and resin surrogates in a clinically derived flow range (60-120 mL/min). Blood-mimicking fluid (BMF) composed of glycerol and water (20%-50% vol/vol) was used to simulate a range of blood viscosities. Microsphere distribution was quantified gravimetrically, and injectate solution was dyed to enable quantification by UV spectrophotometry...
September 15, 2016: Journal of Vascular and Interventional Radiology: JVIR
Florian Nima Fleckenstein, Rüdiger Egbert Schernthaner, Rafael Duran, Jae Ho Sohn, Sonia Sahu, Karen Marshall, MingDe Lin, Bernhard Gebauer, Julius Chapiro, Riad Salem, Jean-François Geschwind
PURPOSE: Liver metastases from renal cell carcinoma (RCC) are not uncommon in the course of disease. However, data about tumor response to intraarterial therapy (IAT) are scarce. This study assessed whether changes of enhancing tumor volume using quantitative European Association for the Study of the Liver (qEASL) on magnetic resonance imaging (MRI) and computed tomography (CT) can evaluate tumor response and predict overall survival (OS) early after therapy. METHODS AND MATERIALS: Fourteen patients with liver metastatic RCC treated with IAT (transarterial chemoembolization: n= 9 and yttrium-90: n= 5) were retrospectively included...
October 2016: Translational Oncology
Maria Umlauft, Piotr Radojewski, Petar-Marko Spanjol, Rebecca Dumont, Nicolas Marincek, Attila Kollar, Philippe Brunner, Jan Beyersmann, Jan Mueller-Brand, Helmut Maecke, Markus Laimer, Martin Walter
: We aimed to assess the risk of developing diabetes mellitus and its effects on all-cause mortality after radiopeptide therapy for neuroendocrine tumors (NET). METHODS: NET patients received somatostatin radiopeptide therapy with yttrium-90-DOTATOC and/or lutetium-177-DOTATOC. The incidence of diabetes mellitus and its mortality were assessed using univariate and multivariate regression. RESULTS: Overall, 1535 NET patients were enrolled, and received 3807 treatment cycles...
September 15, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Justin K Mikell, Armeen Mahvash, Wendy Siman, Veera Baladandayuthapani, Firas Mourtada, S Cheenu Kappadath
PURPOSE: To quantify differences that exist between dosimetry models used for (90)Y selective internal radiation therapy (SIRT). METHODS AND MATERIALS: Retrospectively, 37 tumors were delineated on 19 post-therapy quantitative (90)Y single photon emission computed tomography/computed tomography scans. Using matched volumes of interest (VOIs), absorbed doses were reported using 3 dosimetry models: glass microsphere package insert standard model (SM), partition model (PM), and Monte Carlo (MC)...
July 27, 2016: International Journal of Radiation Oncology, Biology, Physics
Bin Cai, Michael B Altman, Jose Garcia-Ramirez, Jason LaBrash, S Murty Goddu, Sasa Mutic, Parag J Parikh, Jeffrey R Olsen, Nael Saad, Jacqueline E Zoberi
PURPOSE: To develop a safe and robust workflow for yttrium-90 (Y-90) radioembolization procedures in a multidisciplinary team environment. METHODS AND MATERIALS: A generalized Define-Measure-Analyze-Improve-Control (DMAIC)-based approach to process improvement was applied to a Y-90 radioembolization workflow. In the first DMAIC cycle, events with the Y-90 workflow were defined and analyzed. To improve the workflow, a web-based interactive electronic white board (EWB) system was adopted as the central communication platform and information processing hub...
September 8, 2016: Brachytherapy
Rahul Mehta, Kejia Cai, Nishant Kumar, M Grace Knuttinen, Thomas M Anderson, Hui Lu, Yang Lu
We present a probabilistic approach to identify patients with primary and secondary hepatic malignancies as responders or nonresponders to yttrium-90 radioembolization therapy. Recent advances in computer-aided detection have decreased false-negative and false-positive rates of perceived abnormalities; however, there is limited research in using similar concepts to predict treatment response. Our approach is driven by the goal of precision medicine to determine pretherapy fluorine-18-2-fluoro-2-deoxy-d-glucose positron emission tomography and computed tomography imaging parameters to facilitate the identification of patients who would benefit most from yttrium-90 radioembolization therapy, while avoiding complex and costly procedures for those who would not...
September 6, 2016: Technology in Cancer Research & Treatment
Michael J Magnetta, Anish Ghodadra, Steven J Lahti, Minzhi Xing, Di Zhang, Hyun S Kim
PURPOSE: To determine whether pathologic colorectal tumor KRAS mutation status is correlated with progression-free survival (PFS) by imaging after selective internal radiation therapy with Yttrium-90 (SIRT Y90) for metastatic colorectal cancer in the liver (mCRC). MATERIALS AND METHODS: This was an IRB approved, HIPAA compliant retrospective cohort study. Consecutive patients with unresectable mCRC with documented KRAS mutation status treated at a single center from 2002 to 2013 with SIRT Y90 were investigated...
September 6, 2016: Abdominal Radiology
Parul Thakral, Suhas Singla, Atul Vashist, Madhav P Yadav, Santosh K Gupta, Jaya S Tyagi, Atul Sharma, Chandra S Bal, EmptyYN Y Snehlata, Arun Malhotra
BACKGROUND AND OBJECTIVES: The aim of the study is to evaluate the therapeutic efficacy and safety of Yttrium- 90 radiolabelled chimeric anti CD20 antibody-Rituximab in the treatment of patients with relapsed/ refractory B cell Non-Hodgkins Lymphoma (NHL). METHODS: Twenty patients with relapsed/refractory CD20+ NHL in progressive state were included in the study. These patients had undergone a median of 2 (range 2-5) prior standard chemotherapy ± immunotherapy regimens...
2016: Current Radiopharmaceuticals
Riad Salem, Andrew C Gordon, Samdeep Mouli, Ryan Hickey, Joseph Kallini, Ahmed Gabr, Mary F Mulcahy, Talia Baker, Michael Abecassis, Frank Miller, Vahid Yaghmai, Kent Sato, Kush Desai, Bartley Thornburg, Al B Benson, Alfred Rademaker, Daniel Ganger, Laura Kulik, Robert J Lewandowski
BACKGROUND AND AIMS: Conventional transarterial chemoembolization (cTACE) is used to treat patients with hepatocellular carcinoma (HCC). Radioembolization is a minimally invasive procedure that involves implantation of radioactive micron-sized particles loaded with yttrium-90 (Y90) inside the blood vessels that supply a tumor. We performed a randomized, phase 2 study to compare the effects of cTACE and Y90 radioembolization in patients with HCC. METHODS: From October 2009 through October 2015, we reviewed patients with HCC of all Barcelona Clinic Liver Cancer (BCLC) stages for eligibility...
August 26, 2016: Gastroenterology
Armeen Mahvash, Ravi Murthy, Bruno C Odisio, Kanwal Pratap Raghav, Lauren Girard, Sheree Cheung, Van Nguyen, Joe Ensor, Sameer Gadani, Khaled M Elsayes, Reham Abdel-Wahab, Manal Hassan, Ahmed S Shalaby, James C Yao, Michael J Wallace, Ahmed O Kaseb
PURPOSE: The safety and efficacy of the combined use of sorafenib and yttrium-90 resin microspheres (Y90 RMS) to treat advanced hepatocellular carcinoma (HCC) is not well established. We determined the incidence of adverse events with this combination therapy in patients with advanced HCC at our institution and analyzed the treatment and survival outcomes. MATERIALS AND METHODS: We reviewed the records of 19 patients with Barcelona Clinic Liver Cancer class B or C HCC who underwent treatment with Y90 RMS (for 21 sessions) while receiving full or reduced doses of sorafenib between January 2008 and May 2010...
2016: J Hepatocell Carcinoma
Andrew C Gordon, Riad Salem, Robert J Lewandowski
No abstract text is available yet for this article.
September 2016: Journal of Vascular and Interventional Radiology: JVIR
Shyam M Srinivas, Elie C Nasr, Vamsi K Kunam, Jennifer A Bullen, Andrei S Purysko
BACKGROUND: Given the differences in size, specific activity, and dosing methods for glass yttrium-90 microspheres ((90)Y-glass) and resin (90)Y microspheres ((90)Y-resin), these therapies may expose the liver to different amounts of radiation, thereby affecting their efficacy and tolerability. We aimed to compare the prescribed activity of (90)Y-glass and (90)Y-resin for real-world patients undergoing selective internal radiation therapy (SIRT) for liver-dominant metastatic colorectal cancer (mCRC) and to assess efficacy and safety outcomes in these patients...
August 2016: Journal of Gastrointestinal Oncology
Johannes M Ludwig, Di Zhang, Minzhi Xing, Hyun S Kim
OBJECTIVE: To investigate comparative effectiveness of drug-eluting bead transarterial chemoembolization (DEB-TACE) versus Yttrium-90 ((90)Y)-radioembolization for hepatocellular carcinoma (HCC). METHODS: Studies comparing conventional (c)TACE versus (90)Y-radioembolization or DEB-TACE for HCC treatment were identified using PubMed/Medline, Embase, and Cochrane databases. The adjusted indirect meta-analytic method for effectiveness comparison of DEB-TACE versus (90)Y-radioembolization was used...
August 25, 2016: European Radiology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"